Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer

Université de Montréal

$65,000.00

Investigating the Role of Bromodomain Proteins in Breast Cancer Chemotherapy Response

FY 2023-24

Summary
Breast cancer is a leading cause of death in Canadian women, with triple-negative breast cancer being especially aggressive. Patients primarily rely on chemotherapy, but drug resistance is common, leading to tumor recurrence and spread. Our research focuses on epigenetic modifications - which dictate how cells change their identity - in this challenging cancer type. We found that inhibiting certain proteins controlling these modifications enhances tumor sensitivity to chemotherapy. Our goal is to understand how these proteins affect chemotherapy response and exploit them pharmacologically to enhance treatment efficacy and prevent drug resistance. Ultimately, this research could lead to new strategies to impair the progression of these aggressive tumors and improve patient outcomes.
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
516993
Name
Deblois Genevieve
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Investigating the Role of Bromodomain Proteins in Breast Cancer Chemotherapy Response
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
Breast cancer is a leading cause of death in Canadian women, with triple-negative breast cancer being especially aggressive. Patients primarily rely on chemotherapy, but drug resistance is common, leading to tumor recurrence and spread. Our research focuses on epigenetic modifications - which dictate how cells change their identity - in this challenging cancer type. We found that inhibiting certain proteins controlling these modifications enhances tumor sensitivity to chemotherapy. Our goal is to understand how these proteins affect chemotherapy response and exploit them pharmacologically to enhance treatment efficacy and prevent drug resistance. Ultimately, this research could lead to new strategies to impair the progression of these aggressive tumors and improve patient outcomes.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Deblois, Genevieve
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~